#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Candida infection Subdural haematoma Chemical burn Erythema Keratosis follicular Lymphangioma Desmoid tumour Thalassaemia beta Haemophilia A with anti factor VIII Biliary cancer metastatic Chronic graft versus host disease in intestine Postprandial hypoglycaemia Dermatitis Oropharyngeal cancer recurrent Pyruvate kinase deficiency anaemia More trials…

    Learn about Rare Diseases

    Loeys-Dietz syndrome Gastrointestinal stromal tumour – Life with Disease Cytokine release syndrome – Basic Information Von Willebrand’s disease – Diagnostics Kearns-Sayre syndrome – Treatment Immunodeficiency congenital Primary mediastinal large B-cell lymphoma – Diagnostics Glomerulonephritis rapidly progressive – Life with Disease Toxic epidermal necrolysis – Diagnostics Friedreich’s ataxia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Paltusotine Oxybuprocaine Laronidase Mebendazole Rbl005.3 Censavudine Sargramostim Norucholic Acid Ergocalciferol Avb-101 Autologous Chondrocytes TEV-53408 Mebeverine Hydrochloride Caspofungin Vortioxetine Poloxamer 407 Varnimcabtagene Autoleucel Batoprotafib Piritramide Aluminium Oxide More therapies…

    Learn about Your Condition

    Autism spectrum disorder Oropharyngeal cancer Pulmonary embolism Breast cancer stage III Haemorrhage intracranial Procedural haemorrhage Neuralgia Open angle glaucoma Diffuse large B-cell lymphoma Acquired haemophilia Craniocerebral injury Peritoneal cancer index Malignant melanoma HIV infection Prostate cancer recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Atypical haemolytic uraemic syndrome

  • Study of Eculizumab in Adults with Hypertensive Emergency-Related Hemolytic Uremic Syndrome Requiring Dialysis or with Severe Kidney Problems

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Atypical haemolytic uraemic syndrome
    Investigated Drugs:
    • Eculizumab
    France

  • Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Atypical haemolytic uraemic syndrome
    Investigated Drugs:
    • Iptacopan
    France Germany Italy Spain

  • Study on Long-Term Safety and Effects of Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Atypical haemolytic uraemic syndrome
    Investigated Drugs:
    • Iptacopan
    Czechia France Germany Italy Spain

  • Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Crovalimab
    Belgium France Hungary Italy Poland Spain

  • Study on the Effects and Safety of Crovalimab for Adults and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Atypical haemolytic uraemic syndrome
    Investigated Drugs:
    • Crovalimab
    Belgium France Germany Hungary Italy Poland +1

  • Study on the Effectiveness and Safety of Iptacopan for Adults with Atypical Hemolytic Uremic Syndrome Not Previously Treated with Complement Inhibitors

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Atypical haemolytic uraemic syndrome
    Investigated Drugs:
    • Iptacopan
    Austria Czechia Greece Slovakia Slovenia
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!